A Phase 1 interventional study of insulin icodec and Insulin glargine U100 in Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 1 site in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2021-03-08.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S — 2 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Novo Nordisk A/S.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 133rd largest by enrollment of the 149 interventional ones that give a count, is one of 8 that started in 2018, is one of 74 in phase 1, and was the 203rd registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Germany
Ages 18–55
Novo Nordisk A/S · Sites in Japan
By country, each count listing its studies:
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 20 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
226 studies; the count open now beside each. This study's row is marked.
First in 1989; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 62 across the 149 interventional studies, 1,068 across the 77 observational. Of the 220 that completed or were terminated, 33 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
3 of the studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT07160816Novo Nordisk A/SA Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar | 2027-01-20 |
| NCT06807190Novo Nordisk A/SGeneral Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will look at how insulin 287 works, if it is safe and the side effects in people who are Japanese with type 1 diabetes. The study will test how insulin goes through your blood, how long it stays there and how the blood sugar is lowered. Insulin 287 is a new medicine. Insulin glargine is already approved to treat diabetes. The study doctors can prescribe insulin glargine. The participants will get both of the insulins in a random order. The participants will get 8 weekly doses of insulin 287 and 14 daily doses of insulin glargine. There will also be a run-in period of 2 days to 7 weeks when the participants inject insulin glargine every day before they start insulin 287 period or insulin glargine period. All doses will be injected under the skin. During the run-in period, the participants adjust the insulin glargine dose and make their blood sugar levels stable. From the run-in period, the participants will take insulin aspart as bolus insulin. The study will last for about 16 - 28 weeks. The participants will have 24 visits with the study doctor. There will be 3 glucose clamps where the participants' blood sugar is tested over time. The participants cannot be in the study if the study doctor thinks that there are risks for their health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised. After run-in, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic (PK) sampling where subjects are treated with once daily (OD) insulin glargine. After insulin 287 treatment, participants will receive insulin glargine U100 OD for 2 weeks.
Drug: insulin icodec · Drug: Insulin glargine U100
Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised. After run-in, participants will receive insulin glargine U100 OD for 2 weeks followed by 1-14 days (at least 1 day is mandatory) of continued insulin glargine treatment. After insulin glargine treatment, participants will receive insulin 287 OW for 8 weeks and subsequent 4 weeks of terminal PK sampling.
Drug: insulin icodec · Drug: Insulin glargine U100
Participants will receive subcutaneous (s.c.) injections of insulin 287 once weekly for 8 weeks
Also known as: Insulin 287
Participants will receive s.c. injections of insulin glargine once weekly for 2 weeks
AUCI287τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state
Measured in pmol\*h/L
Time frame: From 0 to 168 hours after trial product administration (day 50)
Number of adverse events (AEs)
Number of events
Time frame: From first trial product administration (day 1) to end of last dosing interval (day 57 for insulin 287, day 15 for IGlar)
Number of hypoglycaemic episodes
Number of episodes
Time frame: From first trial product administration (day 1) to end of last dosing interval (day 57 for insulin 287, day 15 for IGlar) excluding clamp days
Change in antiinsulin 287 antibody level
Measured in % B/T (percentage of bound tracer measured after precipitation to total tracer)
Time frame: From first insulin 287 administration (day 1) to follow-up visit (day 106)
Change in antiinsulin 287 antibody titres
Number of dilutions. The antibody titer is calculated by diluting the blood serum sample containing antibody in serial ratios (1:2, 1:4, 1:8, 1:16... and so on). Using an appropriate detection method (e.g., colorimetric, chromatographic, etc.), each dilution is tested for the presence of detectable levels of antibody. The assigned titer value is indicative of the last dilution in which the antibody was detected.
Time frame: From first insulin 287 administration (day 1) to follow-up visit (day 106)
Positive cross-reactive anti-human insulin antibodies
Yes/no. Number of participants who developed/not developed positive cross-reactive anti-human insulin antibodies.
Time frame: At follow-up visit (day 106)
AUCI287,0-168,FD - Area under the serum insulin 287 concentration-time curve after the first dose
Measured in pmol\*h/L
Time frame: From 0 to 168 hours after trial product administration (day 1)
tmax,I287,FD - Time to maximum observed serum insulin 287 concentration after the first dose
Measured in hours
Time frame: From 0 to 168 hours after trial product administration (day 1)
Cmax,I287,FD - Maximum observed serum insulin 287 concentration after the first dose
Measured in pmol/L
Time frame: From 0 to 168 hours after trial product administration (day 1)
tmax,I287,SS - Time to maximum observed serum insulin 287 concentration after the last dose
Measured in hours
Time frame: From 0 to 168 hours after trial product administration (day 50)
Cmax,I287,SS - Maximum observed serum insulin 287 concentration after the last dose
Measured in pmol/L
Time frame: From 0 to 168 hours after trial product administration (day 50)
t1/2,I287,SS - Terminal half-life for insulin 287 at steady state
Measured in hours
Time frame: Terminal part of the serum insulin 287 concentration-time curve where the curve is well approximated by a straight line on logarithmic scale after last trial product administration (day 50)
CI287,trough - Serum insulin 287 trough concentration
Measured in pmol/L
Time frame: Measured at the end of each dosing interval 168 hours after dosing (day 8, 15, 22, 29, 36, 43, 50 and 57)
AUCIGlar,τ,SS - Area under the serum IGlar concentration-time curve during one dosing interval at steady state
Measured in pmol\*h/L
Time frame: From 0 to 24 hours after trial product administration (day 14)
Cmax,IGlar,SS - Maximum observed serum IGlar concentration at steady state
Measured in pmol/L
Time frame: From 0 to 24 hours after trial product administration (day 14)
tmax,IGlar,SS - Time to maximum observed serum IGlar concentration at steady state
Measured in hours
Time frame: From 0 to 24 hours from trial product administration (day 14)
CIGlar,trough - Serum IGlar trough concentration
Measured in pmol/L
Time frame: Measured at the end of each dosing interval 24 hours after trial product administration (day 7, 14 and 15)
AUCGIR,24-48h,SS - Area under the glucose infusion rate-time curve at steady state
Measured in mg/kg
Time frame: From 24 to 48 hours after trial product administration (day 51)
GIRmax,24-48h, SS - Maximum observed glucose infusion rate at steady state
Measured in mg/(kg\*min)
Time frame: From 24 to 48 hours after trial product administration (day 51)
AUCGIR,150-168h,SS - Area under the glucose infusion rate-time curve at steady state
Measured in mg/kg
Time frame: From 150 to 168 hours after trial product administration (day 57)
GIRmax,150-168h,SS - Maximum observed glucose infusion rate at steady state
Measured in mg/(kg\*min)
Time frame: From 150 to 168 hours after trial product administration (day 57)
AUCGIR,0-24h,SS - Area under the glucose infusion rate-time curve at steady state
Measured in mg/kg
Time frame: From 0 to 24 hours after trial product administration (day 14)
GIRmax,0-24h,SS - Maximum observed glucose infusion rate at steady state
Measured in mg/(kg\*min)
Time frame: From 0 to 24 hours after trial product administration (day 14)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Dec 2018 to primary completion in Dec 2019, 12 months.
Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 12 months is above that.
Counting every sponsor, half of 152 studies reached it within 12 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin icodec